Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach

Study ID
NCT00075465

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with epirubicin as first-line therapy works in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the stomach.

More informations

Trial Starting Date

Apr 30,2001

Requirements

Gender All
Minimum age 18 Years
Maximum age 75 Years

Enrollement Limit